Parkman Healthcare Partners LLC purchased a new position in shares of CareDx, Inc. (NASDAQ:CDNA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 202,417 shares of the company’s stock, valued at approximately $5,769,000.
A number of other large investors also recently bought and sold shares of CDNA. BlackRock Inc. purchased a new stake in shares of CareDx during the 2nd quarter valued at $137,219,000. Deerfield Management Company L.P. acquired a new position in CareDx in the third quarter valued at $31,857,000. Boston Partners grew its position in CareDx by 2,776.5% during the fourth quarter. Boston Partners now owns 901,929 shares of the company’s stock valued at $16,994,000 after acquiring an additional 870,574 shares during the period. Millennium Management LLC increased its stake in CareDx by 504.0% during the third quarter. Millennium Management LLC now owns 413,689 shares of the company’s stock worth $6,015,000 after acquiring an additional 345,197 shares during the last quarter. Finally, Palo Alto Investors LP purchased a new position in shares of CareDx in the 3rd quarter worth about $4,598,000.
Insider Activity
In other CareDx news, Director Christine Cournoyer sold 16,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $46.94, for a total value of $751,040.00. Following the completion of the sale, the director owned 42,943 shares of the company’s stock, valued at $2,015,744.42. This trade represents a 27.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Bickerstaff sold 20,000 shares of CareDx stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $46.28, for a total transaction of $925,600.00. Following the sale, the director owned 134,061 shares in the company, valued at $6,204,343.08. This represents a 12.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 114,936 shares of company stock worth $3,770,348 over the last three months. Insiders own 2.40% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Report on CDNA
CareDx Price Performance
Shares of NASDAQ CDNA opened at $47.50 on Tuesday. CareDx, Inc. has a 1-year low of $12.37 and a 1-year high of $49.76. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of 22.95 and a beta of 2.38. The business has a 50-day moving average of $36.31 and a 200-day moving average of $25.58.
CareDx (NASDAQ:CDNA – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.23 by $0.14. The business had revenue of $131.95 million for the quarter, compared to the consensus estimate of $114.05 million. CareDx had a return on equity of 2.87% and a net margin of 24.23%.The company’s revenue was up 52.2% on a year-over-year basis. During the same period last year, the business posted ($0.16) EPS. Research analysts expect that CareDx, Inc. will post 0.47 EPS for the current fiscal year.
About CareDx
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Featured Articles
- Five stocks we like better than CareDx
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc. (NASDAQ:CDNA – Free Report).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
